Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Pulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients.

Sheshadri A, Chemaly RF, Alousi AM, Shah PK, Rondon G, Bashoura L, Kmeid J, Azzi J, Blanco DW, Kaous M, Dickey BF, Champlin RE, Shah DP.

Biol Blood Marrow Transplant. 2018 Dec 3. pii: S1083-8791(18)30755-9. doi: 10.1016/j.bbmt.2018.11.022. [Epub ahead of print]

PMID:
30521974
2.

The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.

El Haddad L, Ariza-Heredia E, Shah DP, Jiang Y, Blanchard T, Ghantoji SS, El Chaer F, El-Haddad D, Prayag A, Nesher L, Rezvani K, Shpall E, Chemaly RF.

J Infect Dis. 2018 Oct 6. doi: 10.1093/infdis/jiy592. [Epub ahead of print]

PMID:
30295846
3.

Risk factors for mortality after respiratory syncytial virus lower respiratory tract infection in adults with hematologic malignancies.

Vakil E, Sheshadri A, Faiz SA, Shah DP, Zhu Y, Li L, Kmeid J, Azzi J, Balagani A, Bashoura L, Ariza-Heredia E, Chemaly RF.

Transpl Infect Dis. 2018 Dec;20(6):e12994. doi: 10.1111/tid.12994. Epub 2018 Sep 21.

PMID:
30195271
4.

Leukopenia and lack of ribavirin predict poor outcomes in patients with haematological malignancies and respiratory syncytial virus infection.

Azzi JM, Kyvernitakis A, Shah DP, El Haddad L, Mahajan SN, Ghantoji SS, Heredia-Ariza E, Chemaly RF.

J Antimicrob Chemother. 2018 Nov 1;73(11):3162-3169. doi: 10.1093/jac/dky311.

PMID:
30113677
5.

Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer.

Liss MA, White JR, Goros M, Gelfond J, Leach R, Johnson-Pais T, Lai Z, Rourke E, Basler J, Ankerst D, Shah DP.

Eur Urol. 2018 Nov;74(5):575-582. doi: 10.1016/j.eururo.2018.06.033. Epub 2018 Jul 12.

PMID:
30007819
6.

Progression of the Radiologic Severity Index predicts mortality in patients with parainfluenza virus-associated lower respiratory infections.

Sheshadri A, Shah DP, Godoy M, Erasmus JJ, Song J, Li L, Evans SE, Chemaly RF, Dickey BF, Ost DE.

PLoS One. 2018 May 17;13(5):e0197418. doi: 10.1371/journal.pone.0197418. eCollection 2018.

7.

Comparison of Palivizumab-Like Antibody Binding to Different Conformations of the RSV F Protein in RSV-Infected Adult Hematopoietic Cell Transplant Recipients.

Ye X, Iwuchukwu OP, Avadhanula V, Aideyan LO, McBride TJ, Ferlic-Stark LL, Patel KD, Piedra FA, Shah DP, Chemaly RF, Piedra PA.

J Infect Dis. 2018 Mar 28;217(8):1247-1256. doi: 10.1093/infdis/jiy026.

PMID:
29365155
8.

Influenza in patients with hematological malignancies: Experience at two comprehensive cancer centers.

Vilar-Compte D, Shah DP, Vanichanan J, Cornejo-Juarez P, Garcia-Horton A, Volkow P, Chemaly RF.

J Med Virol. 2018 Jan;90(1):50-60. doi: 10.1002/jmv.24930. Epub 2017 Sep 14.

9.

Burden of human metapneumovirus infections in patients with cancer: Risk factors and outcomes.

El Chaer F, Shah DP, Kmeid J, Ariza-Heredia EJ, Hosing CM, Mulanovich VE, Chemaly RF.

Cancer. 2017 Jun 15;123(12):2329-2337. doi: 10.1002/cncr.30599. Epub 2017 Feb 8.

10.

Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series.

El Chaer F, Mori N, Shah D, Oliver N, Wang E, Jan A, Doan V, Tverdek F, Tayar J, Ariza-Heredia E, Chemaly RF.

Antiviral Res. 2016 Nov;135:91-96. doi: 10.1016/j.antiviral.2016.08.027. Epub 2016 Sep 1.

PMID:
27594527
11.

How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients.

El Chaer F, Shah DP, Chemaly RF.

Blood. 2016 Dec 8;128(23):2624-2636. Epub 2016 Oct 19.

12.

Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience.

El-Haddad D, El Chaer F, Vanichanan J, Shah DP, Ariza-Heredia EJ, Mulanovich VE, Gulbis AM, Shpall EJ, Chemaly RF.

Antiviral Res. 2016 Oct;134:58-62. doi: 10.1016/j.antiviral.2016.08.024. Epub 2016 Aug 28.

PMID:
27582067
13.

Challenges in Determining Genotypes for Pharmacogenetics in Allogeneic Hematopoietic Cell Transplant Recipients.

Langman LJ, Nesher L, Shah DP, Azzi JM, Shpall EJ, Rezvani K, Black JL 3rd, Chemaly RF.

J Mol Diagn. 2016 Sep;18(5):638-642. doi: 10.1016/j.jmoldx.2016.03.007. Epub 2016 Jun 29.

14.

Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review.

Shah DP, Shah PK, Azzi JM, El Chaer F, Chemaly RF.

Cancer Lett. 2016 Aug 28;379(1):100-6. doi: 10.1016/j.canlet.2016.05.035. Epub 2016 May 31. Review.

15.

Association of increased influenza vaccination in health care workers with a reduction in nosocomial influenza infections in cancer patients.

Frenzel E, Chemaly RF, Ariza-Heredia E, Jiang Y, Shah DP, Thomas G, Graviss L, Raad I.

Am J Infect Control. 2016 Sep 1;44(9):1016-21. doi: 10.1016/j.ajic.2016.03.024. Epub 2016 May 5.

PMID:
27158088
16.

Utility of the Enzyme-Linked Immunospot Interferon-γ-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients.

Nesher L, Shah DP, Ariza-Heredia EJ, Azzi JM, Siddiqui HK, Ghantoji SS, Marsh LY, Michailidis L, Makedonas G, Rezvani K, Shpall EJ, Chemaly RF.

J Infect Dis. 2016 Jun 1;213(11):1701-7. doi: 10.1093/infdis/jiw064. Epub 2016 Feb 11.

17.

Outcomes of Influenza Infections in Hematopoietic Cell Transplant Recipients: Application of an Immunodeficiency Scoring Index.

Kmeid J, Vanichanan J, Shah DP, El Chaer F, Azzi J, Ariza-Heredia EJ, Hosing C, Mulanovich V, Chemaly RF.

Biol Blood Marrow Transplant. 2016 Mar;22(3):542-8. doi: 10.1016/j.bbmt.2015.11.015. Epub 2015 Nov 27.

18.

Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review.

Shah DP, Shah PK, Azzi JM, Chemaly RF.

Cancer Lett. 2016 Jan 28;370(2):358-64. doi: 10.1016/j.canlet.2015.11.014. Epub 2015 Nov 12. Review.

19.

Influenza vaccination in patients with cancer: factors associated with vaccination practices for patients and their household members.

Ariza-Heredia EJ, Azzi J, Shah DP, Nesher L, Ghantoji SS, Michailidis L, Marsh L, Chemaly RF.

Infect Control Hosp Epidemiol. 2015 Oct;36(10):1239-41. doi: 10.1017/ice.2015.150. Epub 2015 Jul 1.

PMID:
26132392
20.

Long-term effectiveness of accelerated hepatitis B vaccination schedule in drug users.

Shah DP, Grimes CZ, Nguyen AT, Lai D, Hwang LY.

Am J Public Health. 2015 Jun;105(6):e36-43. doi: 10.2105/AJPH.2014.302487. Epub 2015 Apr 16.

Supplemental Content

Loading ...
Support Center